Three stories today. An experiment kept a single positron, the antimatter partner of the electron, trapped for months and watched it jump one step at a time from its lowest energy state. Final-stage trial results showed that an mRNA cancer vaccine made separately for each patient cut the risk of melanoma returning by 42 per cent; and in mice, the locus coeruleus, a small region of the brainstem, turned out not to spray the same signal over the whole brain but to send different signals along different routes.
Physics
A team at Northwestern University trapped a single positron, held it in its lowest energy state for months, and measured it stepping up and down in energy one level at a time.
Antimatter is a partner that is the same as ordinary matter in every way except that its electric charge has the opposite sign. The positron, partner of the electron, carries a positive charge. When the two meet they vanish together in a flash of light, so holding antimatter for long is very hard.
Gerald Gabrielse's team at Northwestern slowed fast positrons from radioactive sodium with a tungsten crystal and caught one of them in a trap made of magnetic and electric fields. When the trap was cooled to about 0.3 degrees above absolute zero, the positron settled into its lowest energy state and stayed there for months. Using precisely tuned microwaves, the team made the positron climb and descend the energy ladder one rung at a time, and read its state without disturbing it. The next goal is to measure how strong a tiny magnet the positron is and compare it with the electron.
Through the eyes of the AtlasWhen the equation describing the electron gave two answers, Dirac did not throw the second away; he said there must be a partner with the opposite charge. A few years later the positron was actually found. Now one such partner can be held for months, to check whether it truly differs from the electron by not a hair. If it does, that is a clue to why only matter was left in the universe.
A word of cautionWhat has been achieved is the technique of trapping and handling. The measurement of the positron's magnet strength will come next year at the earliest, and nobody knows whether it will differ from the electron's.
Source · ScienceAlert (Northwestern University · Physical Review Letters)
Life
High-risk melanoma patients given Moderna and Merck's personalised mRNA cancer vaccine together with an immunotherapy drug had a 42 per cent lower risk of the cancer returning or of death than those given the immunotherapy alone.
Melanoma is a cancer of the skin's pigment cells. Even after it is removed by surgery, it often comes back. Cancer cells carry many mutations in their genes, so if the immune system recognises the odd protein fragments those mutations produce, it can attack the cancer cells. The trouble is that the mutations differ from patient to patient.
This vaccine reads the genes of one patient's tumour, picks a few dozen mutated fragments found only in that person's cancer, and puts the blueprint for them into mRNA. Inside the body, the mRNA briefly makes those fragments and shows them to the immune system in advance. In the final-stage trial, given with the immunotherapy drug Keytruda to high-risk stage 3 and 4 patients after surgery, over about two years of follow-up it cut the risk of recurrence or death by 42 per cent compared with Keytruda alone. The risk of spread to distant organs fell by 38 per cent.
Through the eyes of the AtlasJenner gave people cowpox, a mild disease of cattle, to prevent smallpox. This idea of showing the body its enemy's face in advance has lasted more than two hundred years. Today's story stretches the idea to an enemy that is not a virus but a cancer arising in one's own body, with a face that differs from person to person.
A word of cautionIt is not a preventive vaccine but a treatment to reduce recurrence in patients who have already had surgery. The result was a little lower than the earlier phase 2 trial, and whether it works for other cancers is not yet known.
Source · BioPharma Dive (ESMO 2026)
Life
Studying the locus coeruleus in the mouse brainstem, a team at the Allen Institute found that nerve cells running to the cerebrum and those running to the spinal cord do different jobs at different moments.
Deep in the brainstem lies a very small region called the locus coeruleus. Its nerve cells send a substance called noradrenaline all over the brain, sharpening alertness and gathering attention. So until now the locus coeruleus was thought of as a kind of loudspeaker, sounding the same signal across the whole brain at once.
A team at the Allen Institute imaged about 35,000 nerve cells across whole mouse brains and looked at gene activity in nearly 400,000 cells. They found that cells in the upper part of the locus coeruleus reach mainly to the cerebrum, and cells in the lower part reach far down mainly to the brainstem and spinal cord. The cells going to the cerebrum got busy when a mouse had a bad outcome and changed its next choice; the cells going to the spinal cord got busy just before a mouse ignored a reward signal. It was closer to a postal system that sorts by address than to a loudspeaker. One cell's branch was more than 70 centimetres long.
Through the eyes of the AtlasThe brain runs on twenty watts, about as much as one light bulb. To get by on so little power, sending signals only where they are needed is better than spraying them everywhere. Today's story is that even one small region is divided far more finely than we thought.
A word of cautionThis is a mouse experiment. Links to conditions such as depression or attention deficit are questions for future research, not findings.
Source · ScienceDaily (Allen Institute · Nature)